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Kaposi sarcoma (KS), a human herpes virus 8 (HHV-8; also called KSHV)–induced endothe-
lial tumor, develops only in a small fraction of individuals infected with HHV-8. We hy-
pothesized that inborn errors of immunity to HHV-8 might underlie the exceedingly rare 
development of classic KS in childhood. We report here autosomal recessive OX40 defi-
ciency in an otherwise healthy adult with childhood-onset classic KS. OX40 is a co- 
stimulatory receptor expressed on activated T cells. Its ligand, OX40L, is expressed on various 
cell types, including endothelial cells. We found OX40L was abundantly expressed in KS 
lesions. The mutant OX40 protein was poorly expressed on the cell surface and failed to 
bind OX40L, resulting in complete functional OX40 deficiency. The patient had a low propor-
tion of effector memory CD4+ T cells in the peripheral blood, consistent with impaired CD4+  
T cell responses to recall antigens in vitro. The proportion of effector memory CD8+ T cells 
was less diminished. The proportion of circulating memory B cells was low, but the antibody 
response in vivo was intact, including the response to a vaccine boost. Together, these 
findings suggest that human OX40 is necessary for robust CD4+ T cell memory and confers 
apparently selective protective immunity against HHV-8 infection in endothelial cells.
© 2013 Byun et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
Kaposi sarcoma (KS) is an inflammatory neo-
plasm affecting cells of endothelial origin (Ganem, 
2010) first described by Moritz Kaposi (Kaposi, 
1872). The causal infectious agent of all known 
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The three known KS-predisposing genes, IFNGR1, WAS, 
and STIM1, are pleiotropic and expressed in various cell 
types, including leukocytes and nonhematopoietic cells. It 
thus remains unknown which specific cell types and molecu-
lar pathways are critical for the effective control of HHV-8 
infection. We therefore searched for new genetic etiologies of 
classic KS in childhood. We report here the discovery and 
characterization of autosomal recessive complete OX40 defi-
ciency in a young adult with childhood-onset classic KS, sug-
gesting a nonredundant role of OX40 in T cell–mediated 
defense against HHV-8.
RESULTS
Homozygous TNFRSF4 (OX40) mutation in a patient  
with childhood-onset classic KS
We investigated a 19-yr-old Turkish woman diagnosed with 
classic KS at the age of 14 yr (II.1 in Fig. 1 A). She had a his-
tory of curable visceral leishmaniasis (VL) at the age of 9 yr 
but remained otherwise healthy. The detailed clinical case re-
port for this patient has been published elsewhere (case 3 in 
Sahin et al. [2010]). The consanguinity of her parents (I.1 and 
I.2), who are HHV-8 seropositive but KS free, suggested that 
susceptibility to KS in this patient followed an autosomal re-
cessive mode of inheritance. For the identification of chro-
mosomal intervals linked to KS, we performed genome-wide 
linkage analysis by homozygosity mapping. Genotype infor-
mation of a healthy sibling (II.3) with positive HHV-8 serol-
ogy was also included in the linkage analysis. In total, we 
identified 37 regions with positive LOD (logarithm of the 
odds) scores, with a combined size of 96 Mb (Table S1). We 
also performed whole-exome sequencing with the patient’s 
genomic DNA. Whole-exome sequencing identified 32,471 
variants, most of which were present in public databases 
(NCBI dbSNP Build 135, 1000 Genomes release 13, and 
Exome Variant Server data release ESP6500SI) or our own 
database (>600 whole-exome sequences from patients with 
conditions other than KS). Of the 520 variants unique to the 
patient, 25 were homozygous, 5 of which were within the 
linked intervals (Table S2). Two resulted in amino acid se-
quence changes: a missense variant of OXA1L and a missense 
variant of TNFRSF4. The OXA1L variant was considered 
unlikely to be damaging because the affected residue was not 
evolutionarily conserved and the missense variation was pre-
dicted to be benign by both PolyPhen-2 (Adzhubei et al., 
2010) and SIFT (Kumar et al., 2009). In addition, its sur-
rounding region was homozygous in another healthy sibling 
(II.2). Although the HHV-8 serology for II.2 was unknown, 
he had likely been exposed to HHV-8 via close contact with 
the other family members (Plancoulaine et al., 2000). In con-
trast, the TNFRSF4 variant was heterozygous in II.2 (Fig. 1 A). 
This variant was a strong candidate because TNFRSF4 en-
codes OX40 (CD134), a co-stimulatory molecule which has 
been implicated in long-term T cell immunity (Croft, 2010). 
OX40 belongs to the TNF receptor (TNFR) superfamily, a 
group of type I membrane proteins. The missense variant p.
forms of KS is human herpes virus 8 (HHV-8), also known 
as KS-associated herpes virus (KSHV; Chang et al., 1994). 
More than 100 million people are infected with HHV-8, with 
a heterogeneous worldwide distribution (Plancoulaine et al., 
2002). Infection with HHV-8 is asymptomatic in the vast 
majority of cases (Wang et al., 2001; Andreoni et al., 2002). 
Only a very small proportion of HHV-8–infected individuals 
develop KS in their lifetime (Davidovici et al., 2001). Ac-
quired immunodeficiency is a strong KS-predisposing fac-
tor; HIV coinfection (epidemic KS) and transplantation-related 
immunosuppression (iatrogenic KS) increase the risk of KS 
by factors of at least 3,000 and 100, respectively (Jensen et al., 
1999; Serraino et al., 2005; Shiels et al., 2011). Idiopathic 
cases of KS, striking otherwise healthy individuals with no 
overt immunological deficit, are mostly reported in the Medi-
terranean Basin (classic KS) and sub-Saharan Africa (endemic 
KS). Classic KS is typically an indolent disease of the skin oc-
curring predominantly in the elderly (median age of onset: 
65 yr; Iscovich et al., 2000). Classic KS is exceedingly rare in 
children, with fewer than 40 cases reported since 1960 (Dutz 
and Stout, 1960; Bisceglia et al., 1988; Akman et al., 1989; 
Zurrida et al., 1994; Landau et al., 2001; Ferrari et al., 2002; 
Hussein, 2008; Sahin et al., 2010; Salem et al., 2011; Cakir et al., 
2013). The data available before the HIV epidemic suggest that 
endemic KS is usually more aggressive than the classic form, af-
fecting a younger population (median age of onset: 40 yr), with 
frequent lymph node involvement (Boshoff and Weiss, 2001). 
Endemic KS in childhood was rare in Africa in the years before 
the HIV epidemic, although not as rare as the classic form 
(Taylor et al., 1972). The rarity of childhood KS contrasts with 
the relatively high seroprevalence of HHV-8 infection in chil-
dren <15 yr of age in the Mediterranean region and in Sub-
Saharan Africa (Mayama et al., 1998; Andreoni et al., 1999; 
Gessain et al., 1999). Furthermore, childhood KS, whether it is 
classic or endemic, runs a more aggressive and disseminated 
course in children than in adults (Dutz and Stout, 1960; 
Olweny et al., 1976). Thus, inherited or acquired host factors 
may underlie classic and endemic KS of childhood.
Inherited immunodeficiencies have been described in 
two unrelated children with classic KS and other, concurrent, 
infectious phenotypes: autosomal recessive complete IFN- 
receptor-1 (IFN-R1) deficiency in a Turkish child with 
KS and mycobacterial disease (Camcioglu et al., 2004) and 
X-linked recessive Wiskott–Aldrich syndrome (WAS) in a 
Tunisian child with KS and EBV lymphoma (Picard et al., 
2006). The observation that some children with isolated, clas-
sic KS were born to consanguineous parents further suggested 
that single-gene inborn errors of immunity might underlie 
such cases (Sahin et al., 2010), as seen in children with other 
isolated life-threatening infectious diseases (Casanova and 
Abel, 2007; Alcaïs et al., 2010). Accordingly, autosomal reces-
sive complete STIM1 deficiency was found in a Turkish child 
with fatal, isolated KS (Byun et al., 2010). Collectively, these 
findings provided evidence that classic KS in childhood, 
whether isolated or associated with other infections, may re-
sult from single-gene inborn errors of immunity to HHV-8. 
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other types of mouse lymphoid cells, including NK and NKT 
cells, but data concerning its expression on cells other than 
T cells in humans remain limited. We investigated the impact 
of the R65C mutation on production of the protein by de-
termining OX40 levels by flow cytometry with a monoclo-
nal antibody, ACT35. No OX40 expression was detectable 
on unstimulated circulating T cells from both healthy con-
trols and the patient (not depicted). OX40 expression was 
strongly induced on PHA-activated CD4+ T cells and to a 
lesser extent on activated CD8+ T cells from healthy controls 
(Fig. 2, A and B). OX40 levels were lower, but not abol-
ished, on the surface of activated T cells from the patient. This 
was not caused by a lack of response to PHA because the in-
duction of CD25 expression was normal on the patient’s T cells 
(not depicted). OX40 levels on the surface of PHA-activated 
T cells from R65C heterozygous family members (I.1, I.2, 
and II.3) were similar to those of healthy controls (Fig. 2, A 
and B). The ectopic production of OX40 in Jurkat or HEK-293 
cells with retroviral expression vectors containing an internal 
ribosomal entry site (IRES) followed by GFP resulted in 
lower levels of R65C mutant protein than of WT protein at the 
cell surface (Fig. 2 C and not depicted). The lower levels of 
Arg65Cys (R65C), resulting from C to T substitution at 
nucleotide position 193 (c.193C>T), affects the first of four 
cysteine-rich domains in the extracellular region of OX40 
(Fig. 1, B and C). The arginine residue in position 65 has not 
been conserved throughout evolution (Fig. 1 D). However, it 
is adjacent to the highly conserved Cys64 residue, which forms 
a disulfide bond with another highly conserved residue, Cys46 
(Compaan and Hymowitz, 2006). Introduction of an additional 
cysteine residue in position 65 may impair the correct disulfide 
bond formation. R65C variation was predicted to be damaging 
by both PolyPhen-2 and SIFT. The homozygous R65C varia-
tion was confirmed by Sanger sequencing (Fig. 1 B). Consis-
tent with an autosomal recessive trait, both parents and two 
siblings of the patient were found to be heterozygous for the 
R65C variation (Fig. 1 A). Finally, the R65C variation was not 
found in 185 Turkish controls and 973 individuals from the 
HGDP-CEPH Human Diversity Panel (Cann et al., 2002), 
further suggesting that it was not an irrelevant polymorphism.
Low levels of mutant OX40 proteins on the cell surface
OX40 is expressed predominantly on activated T cells in 
both humans and mice (Croft, 2010). It has been detected on 
Figure 1. Homozygous TNFRSF4 mutation in a patient with classic KS. (A) Family pedigree with TNFRSF4 allele segregation. The black-filled sym-
bol indicates the patient (P). Anti–HHV-8 antibody titers, assessed in serum samples collected 3 yr after the initial HHV-8 serology (case 3 in Sahin et al. 
[2010]), are indicated in parentheses. Ag, antigen; NA, data not available; Neg, negative. (B) Confirmation of the single nucleotide substitution c.193C>T 
(indicated by an arrowhead) by Sanger sequencing. TNFRSF4 exon 2 was amplified by PCR from genomic DNA from a healthy control and the patient. 
Representative chromatograms for three independent experiments are shown. (C) Schematic representation of OX40 protein structure. Numbers shown 
below the scheme indicate the amino acid residue number. CRD, cysteine-rich domain; CYT, cytosolic domain; SP, signal peptide; TM, transmembrane 
domain. (D) Multiple sequence alignment of human TNFRSF4 and its orthologues. The Arg65 residue of human OX40 (top row) and the corresponding 
residues in the other species are boxed.
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of OX40 were sensitive to endoglycosidase H and resistant 
to O-glycosidase (Fig. 3 B), indicating they had immature, 
high-mannose N-linked carbohydrates and no O-linked car-
bohydrates. Conversely, the higher mol wt forms (50 kD) 
were endoglycosidase H resistant and O-glycosidase sensi-
tive (Fig. 3 B), indicating they had complex N-linked and 
O-linked carbohydrates, these modifications being made in 
the Golgi complex. The biotin labeling of cell surface proteins 
in HEK-293 cells that expressed OX40 ectopically further 
demonstrated that the lower mol wt forms were exclusively 
intracellular (Fig. 3 C). The accumulation of lower mol wt 
forms of OX40 with immature carbohydrates in the patient’s 
cells thus suggests that most of the newly synthesized mutant 
OX40 proteins remained in the ER and did not enter the 
Golgi complex. However, the unfolded protein response (UPR) 
was not activated in the patient’s T cell blasts, as assessed with 
quantitative RT-PCR to measure the induction of BiP/GRP78 
OX40 detected at the cell surface with ACT35 did not result 
from a change in epitope structure because staining with two 
other antibodies, H-133 (polyclonal antibody) and EPR17Y 
(monoclonal antibody), yielded similar results (Fig. 2 C). 
Overall, these data suggest that the R65C mutation impairs 
OX40 expression on the cell surface.
Intracellular accumulation of mutant OX40 proteins
We then performed immunoblotting for OX40 proteins. In 
whole-cell lysates of PHA-activated T cell blasts from healthy 
controls, most of the OX40 proteins migrated with an ap-
proximate mol wt of 50 kD, with a minor fraction observed 
at 35 kD. The patient’s PHA-activated T cell blasts contained 
a much smaller proportion of the 50-kD form and a much 
higher proportion of the 35-kD form (Fig. 3 A). Higher levels 
of the 35-kD form were also observed in R65C heterozygous 
individuals (I.1, I.2, and II.3). The lower mol wt forms (35 kD) 
Figure 2. Low levels of mutant OX40 on the cell surface. (A and B) PBMCs from healthy controls (C), R65C heterozygous family members (I.1, 
I.2, and II.3; Het), and the patient (P) were activated by incubation with PHA for 4 d. Cell surface OX40 levels were determined by flow cytometry with 
the ACT35 monoclonal antibody. Representative histograms and MFI (mean fluorescence intensity) values for three independent experiments are 
shown. (A) Gated on the CD3+CD4+ population (CD4+ T cells). (B) Gated on the CD3+CD8+ population (CD8+ T cells). (C) Jurkat cells were transduced 
with bicistronic retroviruses with an empty vector (Mock) or encoding OX40-WT or OX40-R65C, together with IRES-GFP. The MFI of OX40 on GFP+ 
cells is shown, as assessed with the antibodies indicated and normalized with respect to isotype controls. The mean values of three independent  
experiments are plotted. The error bars indicate the SEM. *, P < 0.05.
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Figure 3. Intracellular accumulation of the mutant OX40 proteins. (A) Immunoblotting of PHA-activated T cell blasts from three healthy controls 
(C1–C3), R65C heterozygous family members (I.1, I.2, and II.3), and the patient (P) was performed with the anti-OX40 monoclonal antibody EPR17Y. 
GAPDH served as a loading control. One experiment representative of three performed is shown. (B) Whole-cell lysates of PHA-activated T cell blasts from 
a healthy control (C) or the patient (P) were treated with the enzymes indicated before immunoblotting. White lines indicate the intervening lanes have 
been spliced out. One experiment representative of two performed is shown. EndoH, endoglycosidase H; NT, nontreated; O-gly+Neu, O-glycosidase and 
neuraminidase. (C) HEK-293 cells transduced with retroviral vectors encoding OX40-WT or OX40-R65C were subjected to cell surface biotinylation. Biotinyl-
ated proteins were isolated with avidin-coated beads. OX40 immunoblotting was performed on whole-cell lysate (WCL), the flow-through fraction (FT), 
and the biotinylated fraction (Biot). A GAPDH blot was used to assess whether the biotinylated fraction was free of intracellular proteins. The results of 
two independent experiments are shown. (D and E) PHA-activated T cell blasts from healthy controls (C1–C3) or the patient (P) were treated with DMSO 
alone or treated with either Brefeldin A (BFA) or tunicamycin (TM) for 6 h. The results of two independent experiments are shown. (D) The mRNA levels of 
BiP/GRP78, relative to GAPDH, were assessed by quantitative RT-PCR. Error bars indicate the SEM. (E) PCR was performed using primer pairs that can 
differentiate various spliced variants of XBP1 mRNA. (F) Whole-cell lysates of HEK-293 cells transduced with retroviral vectors with an empty vector 
(Mock) or encoding OX40-WT, OX40-R65C, or OX40-R65A were resolved by SDS-PAGE under reducing or nonreducing conditions. The arrowheads indi-
cate protein bands unique to the OX40-R65C sample. One result representative of three independent experiments is shown. (G) Jurkat cells were trans-
duced with bicistronic retroviruses with an empty vector (Mock) or encoding OX40-WT, OX40-R65C, or OX40-R65A, together with IRES-GFP. Cell surface 
OX40 levels were assessed with ACT35 by flow cytometry. One result representative of three independent experiments is shown.
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(Fig. 4 D). This was not caused by an intrinsic defect in T cell 
proliferation because the patient’s T cells proliferated normally 
in response to various doses of anti-CD3 antibody alone or 
PHA (Fig. 4 E). The R65C is thus a loss-of-function allele, 
and the patient homozygous for this allele displays complete 
functional OX40 deficiency. These data suggest that two 
mechanisms underlie the loss of function of the R65C mu-
tant allele: (1) a low level of OX40 proteins on the cell surface 
and (2) an abolition of the binding to OX40L of the residual 
OX40 proteins on the cell surface.
Low proportions of nonnaive T cell subsets  
in the peripheral blood
The total number of leukocytes and the proportions of the 
major leukocyte subsets in peripheral blood were normal in 
the patient (Table 1). The proportions of T, B, NK, NKT, and 
 T cells in PBMCs were also similar to those of age-matched 
healthy controls (Table 1). Given the T cell–specific expres-
sion of OX40, we carefully examined various subsets of pe-
ripheral blood T cells. The proportions of CD4+ and CD8+  
T cells in the lymphocyte gate were normal in the patient 
(Table 1). The proportion of naive CD4+ T cells was higher in 
the patient than in healthy controls (Fig. 5 A). This reflected 
the lower proportions of nonnaive subsets, particularly for the 
CD45RACCR7 effector memory (TEM) population, but 
also for the regulatory T and CXCR3+ (enriched in IFN-–
producing T cells [Duhen et al., 2012]) subsets (Fig. 5, A and B). 
The proportions of the CXCR5+ (follicular helper T cells) 
and CCR6+ (enriched in IL-17–producing T cells) subsets were 
similar to those of healthy controls. We also examined CD8+ 
T cell subsets. The proportion of naive CD8+ T cells and that 
of CD8+ TEM were only higher and lower in the patient than 
in healthy controls, respectively (Fig. 5 C). We observed no 
increase in the proportion of the CD45RA+CCR7 TEMRA 
subset, which is often expanded in individuals with chronic 
viral infection, despite the patient suffering from KS over 5 yr 
(Fig. 5 C). Peptide–MHC class I multimer staining showed 
the patient to have low and normal frequencies of circulating 
CMV- and EBV-specific CD8+ T cells, respectively (Fig. 5 D), 
with a TEM phenotype (not depicted). We also investigated the 
levels of various cell surface markers, 2B4, CD127, CD103, 
CLA, CD57, CX3CR1, CD28, CD62L, CD11a, CD11b, 
CD27, CD95, granzyme B, and perforin, the expression of 
which changes during the differentiation of naive CD4+ and 
CD8+ T cells into memory and effector subsets. No overt dif-
ference was noted between the patient and the healthy con-
trols for these markers (not depicted).
Impaired memory CD4+ T cell response to recall antigens
We assessed the function of memory CD4+ T cells in the pa-
tient by measuring cytokine production and proliferation in 
response to a panel of recall antigens in vitro. PBMCs from 
Bacille Calmette-Guérin (BCG)–vaccinated healthy controls 
and BCG-vaccinated R65C heterozygous family members 
secreted large amounts of IFN- in response to purified pro-
tein derivative (PPD; Fig. 6 A). However, the patient’s PBMCs 
mRNA and PCR to detect spliced XBP1 mRNA (Fig. 3, D 
and E). This was not caused by a general defect in the UPR 
pathway because Brefeldin A– or tunicamycin-induced acti-
vation of the UPR was normal (Fig. 3, D and E). Therefore, 
the accumulation of mutant OX40 proteins does not seem to 
induce ER stress.
Introduction of a cysteine at position 65 is deleterious
We hypothesized that the acquisition of an additional cysteine 
residue in position 65 might interfere with correct disulfide 
bond formation. Indeed, multiple bands unique to OX40-R65C 
were observed in nonreducing conditions, probably corre-
sponding to OX40 molecules with abnormal intra- and/or 
intermolecular disulfide bonds (Fig. 3 F, arrowheads). We in-
vestigated the impact of the cysteine residue in position 65 
further by generating an OX40-R65A mutant. No accumu-
lation of lower mol wt forms was observed in HEK-293 cells 
expressing OX40-R65A, and the migration pattern of OX40-
R65A proteins in nonreducing conditions was similar to that 
of OX40-WT proteins (Fig. 3 F). The much lower levels of 
OX40 expression at the cell surface observed in OX40-R65C–
transduced Jurkat and HEK-293 cells were not observed in 
OX40-R65A–transduced cells (Fig. 3 G and not depicted). 
These results suggest that the introduction of a cysteine resi-
due at position 65, rather than the loss of the arginine residue 
normally present, is responsible for the impaired cell surface 
expression of the OX40-R65C mutant proteins.
R65C is a loss-of-function mutation
We then investigated whether the R65C mutation led to a 
functional OX40 deficiency. Human OX40 ligand (OX40L), 
encoded by TNFSF4, is a member of the TNF superfamily 
and a type II membrane protein. Its expression, which is often 
inducible, has been observed in professional antigen-presenting 
cells including dendritic cells, macrophages, and B cells, as 
well as other cell types such as endothelial cells, mast cells, and 
lymphoid tissue inducer cells (Croft, 2010). Its expression on 
endothelial cells is of particular interest, as KS is driven by the 
proliferation of HHV-8–infected endothelial cells (Ganem, 
2010). Despite the expression of residual mutant OX40 on 
the cell surface, binding to soluble recombinant OX40L by 
PHA-activated T cells of the patient was completely abol-
ished (Fig. 4 A). Lentiviral expression of a cDNA encoding 
OX40-WT, but not OX40-R65C, rescued OX40L binding 
in the patient’s T cells (Fig. 4 B). Moreover, binding to OX40L 
was severely impaired in Jurkat cells expressing OX40-R65C, 
as shown by comparison with cells expressing OX40-WT 
(16-fold decrease; Fig. 4 C). This defect is much more severe 
than that in surface expression (three- to fourfold decrease; 
Fig. 2 C). Similar results were obtained with HEK-293 cells 
(Fig. 4 C). We assessed the impact of the R65C mutation on 
T cell co-stimulation in response to membrane-bound OX40L 
by transducing Vero cells with retroviruses encoding human 
OX40L or an empty vector. An OX40L-dependent enhance-
ment of cell proliferation was observed in anti-CD3–activated 
T cells from healthy controls but not in those from the patient 
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Figure 4. R65C is a loss-of-function mutation. (A) PHA-activated T cell blasts from healthy controls (C), R65C heterozygous family members (Het), 
or the patient (P) were incubated with biotinylated recombinant soluble OX40L. Unbound OX40L molecules were washed out, and the levels of cell-bound 
OX40L were measured by flow cytometry with allophycocyanin-labeled streptavidin (SA-APC). Representative histograms and MFIs (mean fluorescence 
intensities) of CD3+CD4+ cells (CD4+ T cells) and CD3+CD8+ cells (CD8+ T cells) in three independent experiments are shown. (B) PHA-activated T cell blasts 
from the patient were transduced with bicistronic lentiviral vectors encoding luciferase (Luc), OX40-WT, or OX40-R65C, together with IRES-RFP. Cell sur-
face OX40 levels measured with ACT35 and binding to OX40L measured with biotinylated recombinant soluble OX40L are shown for CD3+CD4+RFP+ cells. 
One result representative of two independent experiments is shown. (C) OX40L binding to Jurkat or HEK-293 cells transduced with bicistronic retroviruses 
with an empty vector (Mock) or encoding OX40-WT or OX40-R65C, together with IRES-GFP, was assessed as in A. The MFIs of OX40L binding for GFP+ 
cells, normalized with respect to those for isotype controls, are shown. The mean of three independent experiments is shown. Error bars indicate the SEM. 
*, P < 0.05. (D) CFSE-labeled PBMCs from healthy controls (C1–C8) and the patient (P) were incubated for 3 d with 1 ng/ml of plate-bound anti-CD3 anti-
body and Vero cells infected with retroviruses either with an empty vector (Vero-Mock) or encoding OX40L (Vero-OX40L). Percentages of CFSE-diluted 
cells in the CD3+CD4+ population are plotted. One result representative of two independent experiments is shown. (E) CFSE-labeled PBMCs from healthy 
controls (C1–C8) and the patient (P) were incubated for 3 d with the indicated concentrations of plate-bound anti-CD3 antibody or PHA. Percentages of 
CFSE-diluted cells in the CD3+CD4+ population are plotted. One result representative of two independent experiments is shown.
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(i.e., those expressing IgG and IgA) in the patient were in the 
normal range (Fig. 7 B). We also studied B cell differentiation 
in vitro by culturing purified total B cells with CD40L, IL-10, 
IL-21, and CpG. B cells from the patient gave rise to IgM- 
secreting plasmablasts with a frequency similar to that observed 
for healthy controls (Fig. 7 C). In contrast, the frequencies of 
in vitro–generated total IgG-secreting B cells (Fig. 7 D) as 
well as the levels of total (Fig. 7 E) and TT-specific (Fig. 7 F) 
secreted IgG were markedly lower for the patient than 
the controls. This probably reflects the paucity of memory 
B cells in the patients’ sample, as these cells are responsible for 
the production of the vast majority of Ig, especially IgG, in 
in vitro cultures of total B cells (Bryant et al., 2007). Consis-
tent with this defect in memory B cell generation, boosting 
the patient with TT vaccine had no appreciable effect on 
the frequency of antigen-specific memory B cells, as mea-
sured 4 wk after immunization (Fig. 7 F). However, a boost 
TT vaccination in the patient substantially increased the 
serum titer of TT-specific antibody in the patient (Fig. 7 G). 
Moreover, the serum concentrations of total IgG, IgA, IgM, 
and IgE and of IgG subclasses (IgG1: 7,270 mg/liter, IgG2: 
3,850 mg/liter, IgG3: 866 mg/liter, and IgG4: 192 mg/liter) 
were within the normal range in the patient, and the titers of 
various antigen-specific antibodies in the patient’s serum were 
similar to those in healthy family members (Table 2). These 
data, together with the lack of infectious diseases commonly 
observed in antibody-deficient patients (Conley et al., 2009), 
strongly suggest that antibody-mediated immunity is intact in 
the OX40-deficient patient. These data also suggest that OX40–
OX40L interaction is differentially required for the genera-
tion of antigen-specific plasma cells versus memory B cells.
OX40L is highly expressed in KS lesions
The 19-yr-old OX40-deficient patient presented no severe 
infectious or tumoral phenotype other than KS and VL. The 
produced only background levels of IFN-, similar to those 
produced by the cells of healthy controls not vaccinated with 
BCG, despite the patient having been vaccinated twice with 
BCG (Fig. 6 A). Furthermore, no IFN- production by the 
patient’s PBMCs was detectable in response to other recall 
antigens, including tetanus toxoid (TT) and common viruses 
(CMV, varicella zoster virus [VZV], HSV-1, and EBV), although 
positive serological results indicated that the patient had 
been exposed to these antigens (Fig. 6 B and Table 2). The re-
sponses of healthy controls to these recall antigens were vari-
able, but all mounted positive IFN- response to at least two 
of the five non-PPD recall antigens tested (Fig. 6 B). Similar 
results were obtained for IL-10 (Fig. 6, C and D). Proliferative 
responses to these antigens, as assessed by CFSE dilution assay, 
were also weak in the patient’s CD4+ T cells (Fig. 6 E). Block-
ing the OX40–OX40L interaction with neutralizing anti-
OX40L antibodies in a similar in vitro recall response assay 
had no effect on the response of healthy control cells, suggesting 
that a requirement for OX40–OX40L interactions to elicit 
in vitro recall responses was not the underlying cause of the 
defect observed for the patient’s cells in this assay (Fig. 6 F). In-
stead, these results strongly suggest an in vivo deficiency of 
antigen-specific memory CD4+ T cells in the patient.
Low frequency of circulating memory B cells  
but intact antibody response in vivo
OX40L can be expressed on activated B cells, and OX40–
OX40L interactions may promote T cell–dependent B cell 
responses in some instances (Morimoto et al., 2000). We thus 
investigated B cell immunity in the patient. The proportion of 
CD10CD27+ memory B cells within the total B cell popu-
lation was lower and that of CD10CD27 naive B cells was 
higher in the patient than in the age-matched healthy con-
trols (Fig. 7 A). This was not caused by a class-switching defect 
because the proportions of isotype-switched memory B cells 
Table 1. Counts and proportions of circulating leukocytes
Parameter Age of the patient at the time of the determination Normal range
19.0 yr 19.3 yr 19.6 yr
Polymorphonuclear neutrophils (/µl) 3,600 4,200 2,400 1,500–3,500
Lymphocytes (/µl) 1,400 1,400 1,320 1,400–3,300
Monocytes (/µl) 500 500 280 210–730
T cells (CD3+) (% lymphocytes)
Total 71.1 61.4 ND 67.5–77.8
CD4+ 38.9 32.2 31.2 26.8–42.7
CD8+ 21.3 17.7 18.4 22.1–36.8
B cells (CD20+) (% lymphocyte) 7.1 8.7 ND 8.0–18.3
NK cells (CD3CD56+) (% lymphocytes)
CD56dim 7.9 11.4 ND 3.5–12.3
CD56bright 0.29 0.26 ND 0.03–0.67
NKT cells (CD3+V24+V11+) (% CD3+ cells) 0.17 0.32 ND 0.01–0.30
 T cells (CD3+V+) (% CD3+ cells) 7.9 15.7 ND 2.4–6.77
Normal range values are from five age-matched healthy controls.
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But the down-regulation may not be complete, and/or T cells 
may receive OX40L stimulation in trans from the neighbor-
ing cells. In any case, we speculate that KS may have occurred 
in the OX40-deficient patient as a result of the combination 
of the systemic deficiency in CD4+ memory T cells and the 
local deficiency of OX40–OX40L interaction between T cells 
and HHV-8–infected endothelial cells at the disease sites.
DISCUSSION
We describe here autosomal recessive complete OX40 defi-
ciency in a patient with childhood-onset classic KS. Our data 
strongly support a causal relationship between OX40 defi-
ciency and the development of KS in this patient. The homo-
zygous missense mutation in OX40 is the only nonsynonymous 
private variation, found by whole-exome sequencing and 
genome-wide linkage analysis, that segregated with the KS 
phenotype in this kindred. We further demonstrated that 
the patient’s OX40 allele has a complete loss of function 
with in-depth biochemical and cellular characterization. The 
immunological phenotype of the patient largely overlaps with 
that of OX40-deficient mice (Kopf et al., 1999; Pippig et al., 
1999), including, in particular, an impairment of memory 
pathogenesis of KS and VL may involve the systemic CD4+ 
memory T cell deficiency seen in the patient. The essential 
and apparently selective role of OX40 in protective immunity 
to HHV-8, and perhaps to Leishmania, may also reflect the 
tissue tropism of these pathogens. Indeed, the expression of 
OX40L on endothelial cells has been reported previously 
both in vitro (Imura et al., 1996; Kunitomi et al., 2000) and in 
situ (Souza et al., 1999; Papadopoulos et al., 2013). We also 
documented the expression of OX40L on primary lymphatic 
and blood endothelial cells (Fig. 8 A). Furthermore, we ob-
served an abundant expression of OX40L with immunohisto-
chemistry in tumor biopsies from AIDS-related KS patients 
(Fig. 8, B–G). A functional OX40–OX40L interaction be-
tween CD4+ T cells and HHV-8–infected endothelial cells, as 
the antigen-presenting cells, may be required for the genera-
tion of protective immunity to HHV-8 in endothelial cells 
and to prevent the development of KS. Interestingly, we found 
that the expression of OX40L in LANA (HHV-8 latency- 
associated nuclear antigen)-positive cells was lower than that 
of LANA-negative cells lining vascular spaces in the vicinity 
(Fig. 8, B–E). This may be caused by an HHV-8–induced 
down-regulation of OX40L to avoid immune surveillance. 
Figure 5. Lower proportions of circulating nonnaive T cell subsets. (A and B) The proportions of the indicated subsets among CD4+ T cells 
(CD3+CD4+) were assessed in PBMCs collected from five to seven age-matched healthy controls (C) and the patient (P). Two or three independent mea-
surements (of blood drawn at different time points) were performed for the patient (each indicated by a red circle). Mean values are indicated with red 
horizontal bars. The various subsets were defined as follows: naive (CD45RA+CCR7+); TCM, T central memory (CD45RACCR7+); TEM, T effector memory 
(CD45RACCR7); Treg, T regulatory cells (CD25highCD127low); CXCR5+, T follicular helper cells (CD45RACXCR5+); CXCR3+, IFN-–producing T cells (CD45
RACXCR5CXCR3+CCR6); and CCR6+, IL-17–producing T cells (CD45RACXCR5CXCR3CCR6+). (C) Proportions of CD8+ T cell (CD3+CD8+) subsets, 
assessed as in A, are shown. The various subsets were defined as follows: naive (CD45RA+CCR7+); TCM (CD45RACCR7+); TEM (CD45RACCR7); and TEMRA, 
CD45RA+ revertant memory T cells (CD45RA+CCR7). (D) The frequency of antigen-specific CD8+ T cells (CD3+CD8+) in an age-matched control (C) or the 
patient (P) was assessed with HLA-A*0201 multimers loaded with peptides derived from CMV antigen pp65 or EBV antigen BMLF-1.
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developing classic KS in childhood are both exceedingly rare 
events (each estimated to affect less than one in 10 million in-
dividuals [see Materials and methods]). Overall, these data 
strongly suggest that KS in this patient is a consequence of 
OX40 deficiency.
Interestingly, the patient had a history of curable VL at 9 yr 
of age. VL is a parasitic disease caused by Leishmania donovani  
and L. infantum (chagasi). It is fatal if left untreated (Chappuis 
et al., 2007). The estimated annual incidence of VL is much 
higher than that of classic KS in childhood (L. infantum alone 
accounts for 50,000 cases worldwide). The causal relation-
ship between OX40 deficiency and VL in this patient is thus 
less evident, but nonetheless plausible for the following reasons: 
(a) most Leishmania-infected individuals do not develop 
clinical illness, as demonstrated by the relatively high propor-
tions of asymptomatic carriers in endemic areas (0.6–71.3%, 
CD4+ T cell response to recall antigens (Gramaglia et al., 
2000; Croft, 2003, 2010). A defect in CD4+ T cells has been 
observed in other patients with genetic susceptibility to KS: 
the IFN-R1–deficient patient had CD4+ T lymphopenia 
at the time of KS onset (Camcioglu et al., 2004), the WAS pa-
tient presented a severe defect in T cell activation (Picard 
et al., 2006), and although the immunological phenotype of 
the STIM1-deficient KS patient could not be assessed (Byun 
et al., 2010), other individuals with STIM1 deficiency have 
been shown to display impaired CD4+ T cell activation (Fuchs 
et al., 2012). Furthermore, patients with acquired immuno-
deficiencies affecting CD4+ T cells, such as AIDS patients and 
transplant recipients treated with calcineurin inhibitors, present 
an increased risk of developing KS (Lebbé et al., 2008; Shiels 
et al., 2011). Finally, harboring biallelic loss-of-function 
OX40 mutations compromising CD4+ T cell immunity and 
Figure 6. Impaired CD4+ T cell recall antigen response. (A and C) PBMCs from eight healthy controls (C1–C8), an R65C heterozygous family mem-
ber (I.1), and the patient (P) were stimulated with PPD or PHA for 5 d. IFN- (A) or IL-10 (C) levels in the supernatant were measured by ELISA. The dotted 
lines indicate the limit of detection. One result representative of three independent experiments is shown. BCG+, BCG vaccinated; BCG, no prior BCG 
vaccination; NS, nonstimulated. (B and D) IFN- (B) or IL-10 (D) production in response to various recall antigens was assessed as in A and C. Except for 
TT, which was provided as purified protein, the recall antigens were provided as virus-infected crude cell lysate. A lysate of uninfected cells tested in the 
same experiment did not trigger IFN- production (not depicted). The dotted lines indicate the limit of detection. One result representative of three inde-
pendent experiments is shown. (E) CFSE-labeled PBMCs were incubated with the indicated recall antigens for 6 d. T cell proliferation was assessed by 
determining the proportion of cells with CFSE levels lower than the undivided peak. Results are shown for CD4+ T cells (CD3+CD4+). One result representa-
tive of three independent experiments is shown. (F) PBMCs from two healthy controls were incubated with 1 ng/ml of plate-bound anti-CD3 and Vero 
cells infected with retroviruses with an empty vector (Vero-Mock) or encoding OX40L (Vero-OX40L) for 3 d, or PPD or TT for 6 d. PBS, isotype antibody, or 
anti-OX40L antibody was added every other day to a concentration of 1 µg/ml. IFN- levels in the culture supernatant were measured by ELISA. Means 
and SEM from two experiments for one of the healthy controls are shown. **, P < 0.01; ns, not significant.
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which this patient had been exposed. No higher morbidity 
or viral burden was reported in OX40- or OX40L-deficient 
mice than in the corresponding control groups after acute in-
fections with influenza virus, murine CMV, or vaccinia virus, 
despite apparent defects in T cell memory (Hendriks et al., 
2005; Humphreys et al., 2007; Salek-Ardakani et al., 2008). 
However, OX40-deficient mice infected with the clone 13 
isolate of LCMV, which establishes persistent infection in 
mice, failed to clear the virus efficiently (Boettler et al., 2012). 
Thus, studies in mice suggest that OX40 may play an impor-
tant role in controlling immunity to pathogens that persist. 
This may also be the case in humans, as both HHV-8 and 
Leishmania establish persistent infections. However, the pa-
tient seemed to be able to control other persistent pathogens, 
including other herpes viruses, such as EBV and CMV, given 
their low viral loads in the blood (1,724 copies/ml and 102 
IU/ml, respectively). The apparent integrity of central mem-
ory CD4+ T cells, antigen-specific memory CD8+ T cells, 
and antibody response may have been sufficient for protec-
tive immunity against these pathogens. The patient’s specific 
susceptibility to HHV-8 and Leishmania may be a combinato-
rial consequence of the systemic deficit of effector memory 
CD4+ T cells and the absence of OX40–OX40L-mediated 
depending on the region and the method of detection; Michel 
et al., 2011); (b) familial clustering and ethnic differences 
have suggested a role for host genetic factors in determining 
the outcome of VL (Cabello et al., 1995; Ibrahim et al., 1999; 
Khalil et al., 2002; Bucheton et al., 2003); (c) IL-12R1 de-
ficiency was reported as the first genetic etiology of familial 
VL (Sanal et al., 2007), although susceptibility to VL was a 
rare finding in IL-12R1–deficient patients (1 out of 141 
patients; de Beaucoudrey et al., 2010); (d) the risk of devel-
oping clinical VL is higher in patients coinfected with HIV 
(Murray, 1999; Kumar and Nylén, 2012); (e) Leishmania re-
sides in macrophages, which are known to express OX40L; 
(f) an OX40 agonist has been shown to enhance the killing 
of amastigotes in C57BL/6 mice infected with L. donovani 
(Zubairi et al., 2004); and (g) we showed that liver L. infantum 
load was much higher in infected OX40-deficient mice than 
WT mice (unpublished data). The discovery of other genetic 
disorders underlying VL may further elucidate the mecha-
nisms by which OX40 contributes to protective immunity 
against Leishmania.
The narrow infectious phenotype of the OX40-deficient 
patient is intriguing. OX40 is probably not essential for 
immunity to most childhood pathogens, or at least those to 
Table 2. Ig levels and serological results for common viruses
Parameter Patient (normal range) I.1 I.2 II.3
Age (yr) 19 38 36 14
Ig
IgG (g/liter) 12.6 (6.6–12.8) ND ND ND
IgA (g/liter) 1.2 (0.7–3.44) ND ND ND
IgM (g/liter) 0.8 (0.5–1.09) ND ND ND
IgE (IU/ml) 20 (<100) ND ND ND
Specific antibody
EBV
Anti-EBNA IgG (<20)a (U/ml) <3.0 146.0 <3.0 <3.0
Anti-VCA IgG (<20)a (U/ml) 55.0 244.0 <10.0 653.0
Anti-VCA IgM (<40)a (IU/ml) 22.9 ND 1.7 1.5
Parvovirus B19
IgG (<1.1)a 3.5 7.9 32.5 10.4
IgM (<1.1)a 0.1 0.3 0.1 0.1
CMV
IgG (<14.0)a (AU/ml) 82.4 94.8 101.0 100.0
IgM (<22.0)a (AU/ml) <5.0 <5.0 5.46 <5.0
HSV-1 and HSV-2
IgG (<1.1)a 29.7 12.2 >30.0 29.7
VZV
IgG (<150)a (mIU/ml) 764.6 1,315.0 419.3 835.6
Rubella
IgG (<10)a (IU/ml) 135 28 16 35
Mumps
IgG (<50)a 152 120 178 240
Measles
IgG (<16.5)a (AU/ml) 18.0 288.0 >300.0 >300.0
aIndicates the threshold for each assay.
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In animal models, OX40L blockade in vivo has been shown 
to attenuate harmful diseases in many inflammatory and auto-
immune models, including models of asthma, graft versus host 
disease, multiple sclerosis, rheumatoid arthritis, inflammatory 
bowel disease, and transplantation (Croft, 2010). Based on 
these findings, several clinical trials involving biological mol-
ecules targeting OX40 or OX40L are currently being considered 
or are already under way (http://clinicaltrials.gov). However, 
our findings suggest that a prolonged blockade of the inter-
action of OX40 with OX40L may lead to a predisposition to 
KS and perhaps VL. Close monitoring may therefore be war-
ranted in future trials to decrease the likelihood or severity of 
such adverse events.
MATERIALS AND METHODS
Ethics statement. This study was conducted in accordance with the Helsinki 
Declaration, with written informed consent obtained from the patient 
and her family. Approval for this study was obtained from the Rockefeller 
University Institutional Review Board (New York), the Comité de Protection 
des Personnes (CPP) and Institut National de la Santé et de la Recherche 
signaling at the disease site between T cells and endothelial/
macrophage cells. Susceptibility to severe EBV infection in 
patients with X-linked lymphoproliferative disease is a classic 
example of a narrow infectious phenotype caused by the re-
quirement for a specific co-stimulatory receptor–ligand inter-
action between T cells and EBV-infected antigen-presenting 
B cells (Hislop et al., 2010; Palendira et al., 2011, 2012). The 
full spectrum of infectious agents against which OX40- 
dependent immunity is critical will only become clear with 
the follow up of this patient and the identification of addi-
tional OX40-deficient individuals.
Finally, our study has important implications for clinical 
immunology, beyond the field of infectious diseases, in areas 
such as autoimmunity and tumor immunology. OX40 ago-
nists have been shown to be effective for reducing cancer 
burden (Weinberg et al., 2011). Our study suggests that treat-
ment with OX40 agonists might be particularly helpful in 
patients with KS. Conversely, blocking OX40–OX40L inter-
action has been considered a promising approach to the treat-
ment of various diseases in which T cells play a critical role. 
Figure 7. Low frequency of memory B cells but intact antibody response in vivo. (A) The proportions of B cell (CD20+) subsets in PBMCs are 
shown. The various subsets were defined as follows: naive (CD10CD27), transitional (CD10+CD27), and memory (CD10CD27+). (B) The propor-
tions of memory B cells from the patient and healthy controls expressing the indicated surface markers are shown. (C–F) Purified B cells from six age-
matched healthy controls (C) and the patient (P) were cultured in the presence of CD40L, IL-10, IL-21, and CpG for 5 d. The frequencies of total IgM 
(C)- or IgG-secreting B cells (D) were assessed by ELISPOT. The levels of total IgG (E) or TT-specific secreted IgG (F) in the culture supernatant were 
quantified by ELISA. (A–E) Horizontal bars indicate the mean. (G) Anti-TT IgG titer in serum was assessed by ELISA. (F and G) Error bars indicate the SD 
from 6 (F) or 10 (G) healthy controls.
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Figure 8. OX40L is abundantly expressed in KS lesions. (A) Expression of OX40L on the cell surface was assessed with flow cytometry in three types 
of primary endothelial cells: human dermal microvascular lymphatic endothelial cells (LEC), human dermal microvascular blood endothelial cells (BEC), 
and HUVECs. One result representative of two independent experiments is shown. (B–G) OX40L (red) and HHV-8 LANA (brown) expression was assessed by 
immunohistochemistry in frozen tissue sections. Bars, 5 mm. (B–E) AIDS-related KS lesions in lymph node (B), presenting as a submental mass (C), and in 
skin (D and E) show HHV-8–positive cells (punctate nuclear brown staining) as well as numerous OX40L-positive cells. (F and G) Non-KS tissues used as 
controls include normal lymph node (F) and skin with mycosis fungoides (G), showing OX40L in cells lining vascular spaces.
Médicale (France), and the human research ethics committees of the St. Vincent’s 
Hospital and Sydney South West Area Health Service (Australia).
Case report. The detailed clinical case report for this patient has been pub-
lished elsewhere (case 3 in Sahin et al. [2010]). Since the initial KS diagnosis, 
she has been sequentially treated with IFN-, vinblastine, etoposide, and 
pegylated liposomal doxorubicin hydrochloride, with a partial response. The 
visceral lesions of KS regressed upon treatment, but widespread dermal lesions 
on the arms and legs remained. Blood samples were taken for leukocyte 
phenotyping and functional studies at least 6 mo after the last treatment. 
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(Santa Cruz Biotechnology, Inc.) and actin (Abgent) were used as for loading 
controls. When indicated, cell lysates were treated with endoglycosidase H or 
a combination of O-glycosidase and neuraminidase (New England Biolabs, 
Inc.) according to the manufacturer’s instructions. Cell surface biotinylation 
was performed with the Pierce Cell Surface Protein Isolation kit (Thermo 
Fisher Scientific) according to the manufacturer’s instructions.
Monitoring the UPR activation. PHA-activated T cell blasts were gener-
ated from PBMCs. T cell blasts were treated with DMSO alone, 1 µg/ml 
Brefeldin A (GolgiPlug; BD), or 1 µg/ml tunicamycin (Sigma-Aldrich) for 6 h. 
mRNA was extracted from the cells with an RNeasy Mini kit (QIAGEN), 
from which we synthesized cDNA with SuperScript III Reverse transcrip-
tion (Life Technologies). For quantitative RT-PCR of BiP and GAPDH, we 
used TaqMan gene expression assays for human HSPA5 (Hs00607129_gH; 
Applied Biosystems) and human GAPDH endogenous control (4310884E; 
Applied Biosystems). The following primer pair was used to detect the spliced 
variant of XBP1 by PCR: 5-TTACGAGAGAAAACTCATGGCC-3 and 
5-GGGTCCAAGTTGTCCAGAATGC-3. The PCR products were sep-
arated and visualized in a 4% agarose gel.
Flow cytometry. Fluorochrome-conjugated antibodies against human 
CD3, CD4, CD8, CD10, CD20, CD25, CD27, CXCR5, CXCR3, IgD, IgM, 
IgG, IgA (BD), ACT35 clone directed against OX40, CD45RA (eBiosci-
ence), CCR7 (R&D Systems), CCR6, CD56, CD127, V (BioLegend), 
V24, and V11 (Beckman Coulter) and the Live/Dead kit (Life Technolo-
gies) were used according to the manufacturers’ instructions. Other antibod-
ies against OX40, H-133 (Santa Cruz Biotechnology, Inc.), and EPR17Y 
(Epitomics) were used with Alexa Fluor 568–conjugated anti–rabbit Ig 
(Molecular Probes). Biotinylated recombinant human OX40L (Ancell) binding 
was detected with allophycocyanin-conjugated streptavidin (eBioscience). 
Virus-specific CD8 T cells were identified by staining PBMCs with specific 
soluble peptide–MHC multimers. CMV-specific cells were identified with 
HLA-A*0201–restricted pentamers (ProImmune) loaded with the NLVPM-
VATV peptide derived from pp65 (UL83) protein, and EBV-specific cells 
were identified with HLA-A*0201–restricted dextramers (Immudex) loaded 
with the GLCTLVAML peptide, derived from the lytic antigen BMLF-1. All 
data were collected on an LSRII flow cytometer (BD) and analyzed with 
FlowJo software (Tree Star).
Recall antigen assay. PBMCs were labeled with 1 µM CFSE at room tem-
perature, in PBS supplemented with 5% FBS. CFSE-labeled PBMCs were 
incubated with various recall antigens for 5–6 d in RPMI 1640 supple-
mented with 10% FBS. The final concentrations and the source of recall anti-
gens were as follows: 5 µg/ml tuberculin PPD, 7 Lf/ml TT (Statens Serum 
Institut), uninfected normal human dermal fibroblast (NHDF) extract, 
CMV-infected NHDF extract, VZV-infected NHDF extract, uninfected Vero 
cell extract, HSV-1–infected Vero cell extract, and 2.5–5 µg/ml EBV-infected 
human B cell extract (EastCoast Bio). PHA (Sigma-Aldrich) was used at a 
concentration of 5 µg/ml as a positive control. ELISA for cytokines was per-
formed according to the manufacturer’s protocol for IFN- (R&D Systems) 
and IL-10 (PeliPair).
In vitro B cell differentiation. Total B cells were purified from the OX40 
patient as well as from six healthy controls using the Dynal negative selection 
kit (Invitrogen). B cells were cultured for 5 d with CD40L, 100 U/ml IL-10 
(gift from DNAX), 50 ng/ml IL-21 (PeproTech), and 1 µg/ml CpG (Sigma-
Aldrich). The frequency of IgM- and IgG-secreting cells was then deter-
mined by ELISPOT. Levels of total and TT-specific IgG in the 5-d culture 
were determined by ELISA (Avery et al., 2010).
Primary endothelial cells. Lymphatic endothelial cells (Lonza CC-2810), 
blood endothelial cells (Lonza CC-2811), and HUVECs (Lonza C2517A) 
were purchased from Lonza and cultured and maintained according to the 
manufacturer’s instruction. The levels of TNF superfamily members on the 
cell surface were measured by flow cytometry. All data were collected on an 
LSRII flow cytometer and analyzed with FlowJo software.
HHV-8 viremia, assessed by quantitative real-time PCR using primers spe-
cific to HHV-8 vCyclin, was negative in genomic DNA extracted from the 
patient’s PBMCs.
Genotyping and linkage analysis. The patient and her parents were gen-
otyped with the Affymetrix Genome-wide SNP 6.0 array, and the two unaf-
fected siblings were genotyped with Affymetrix GeneChip Human Mapping 
250K array. Genotype calling was achieved with Affymetrix Power Tools. We 
discarded monomorphic single nucleotide polymorphisms (SNPs), SNPs 
with a call rate <100%, and SNPs presenting more than one Mendelian in-
consistency within the family. SNPs were further filtered with population-
based filters. We then used 108,355 high-quality SNP markers to carry out 
linkage analysis, assuming autosomal recessive inheritance with complete 
penetrance (homozygosity mapping). Parametric multipoint linkage analysis 
was carried out with Merlin software (Abecasis et al., 2002). The Turkish 
family founders and HapMap CEU trios were used to estimate allele fre-
quencies and to define linkage clusters, with an r2 threshold of 0.4.
Whole-exome sequencing. Exome capture was performed with the Sure-
Select Human All Exon 50 Mb kit (Agilent Technologies). Paired-end se-
quencing was performed on a HiSeq 2000 (Illumina) generating 100-base 
reads. We aligned the sequences with the GRCh37 reference build of the 
human genome using the BWA aligner (Li and Durbin, 2009). Downstream 
processing and variant calling were performed with the Genome Analysis 
Toolkit (GATK; McKenna et al., 2010), SAMtools (Li et al., 2009), and 
Picard. Substitution and InDel calls were made with GATK Unified Geno-
typer. All calls with a read coverage ≤2x and a Phred-scaled SNP quality of 
≤20 were filtered out. All variants were annotated using an annotation soft-
ware system that was developed in-house.
Cell lines and retroviral and lentiviral transduction. Jurkat cells (ATCC) 
were grown in RPMI 1640 supplemented with 10% FBS. HEK-293 and 
Vero cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Medium sup-
plemented with 10% FBS. The human TNFRSF4 cDNA (OriGene) was in-
serted into pMSCV-IRES-GFP (pMIG-OX40-WT). Site-directed mutagenesis 
was performed with the following primer pairs (bold indicates the base pairs 
in which mutations were introduced): 5-GAACACGGTGTGCTGTC-
CGTGCGGG-3 and 5-CCCGCACGGACAGCACACCGTGTTC-3 
for pMIG-OX40-R65C and 5-GAACACGGTGTGCGCTCCGTGC-
GGGC-3 and 5-GCCCGCACGGAGCGCACACCGTGTTC-3 for 
pMIG-OX40-R65A. Replication-incompetent retroviruses were produced 
with the GP2-293 packaging cell line (Takara Bio Inc.). Jurkat and HEK-293 
cells were transduced with retroviruses in the presence of 3 µg/ml Poly-
brene (InvivoGen). Successfully transduced cells were identified as having a 
GFP signal (30–90% of live cells were GFP positive at the time of analysis). 
OX40-expressing lentiviral constructs were generated as previously described 
(Schoggins et al., 2011) with Gateway cloning technology (Life Technolo-
gies). In brief, OX40-WT and -R65C coding sequences were amplified by 
PCR from pMIG-OX40-WT and -R65C, respectively, with oligonucleo-
tides containing attB sites flanking the coding sequence. The destination 
vector pTRIP.CMV.IVSb.iresTagRFP_Dest was provided by C. Rice (The 
Rockefeller University, New York, NY). Replication-incompetent lentivi-
ruses were produced in HEK-293T cells and concentrated with Lenti-X 
concentrator (Takara Bio Inc.). PBMCs were activated by incubation with 
5 µg/ml PHA for 24 h before the addition of lentiviruses. After 72 h of incu-
bation with lentiviruses, cells were analyzed by flow cytometry. Successfully 
transduced cells were identified as positive for RFP (10–30% of live cells 
were RFP positive at the time of analysis).
Western blotting. Whole-cell lysates were prepared by incubating cell pel-
lets with NP-40 lysis buffer (10 mM Tris HCl, pH 7.5, 150 mM NaCl, and 
1% IGEPAL CA-630 [Sigma-Aldrich]) for 30 min on ice and then centri-
fuging at 20,000 g. OX40 immunoblotting was performed with a rabbit 
monoclonal antibody, EPR17Y (Epitomics). Antibodies against GAPDH 
o
n
 N
ovem
ber 4, 2016
D
ow
nloaded from
 
Published July 29, 2013
JEM Vol. 210, No. 9 
Article
1757
predicting damaging missense mutations. Nat. Methods. 7:248–249. 
http://dx.doi.org/10.1038/nmeth0410-248
Akman, E.S., U. Ertem, V. Tankal, A. Pamir, A.M. Tuncer, and O. Uluoğlu. 
1989. Aggressive Kaposi’s sarcoma in children: a case report. Turk. J. 
Pediatr. 31:297–303.
Alcaïs, A., L. Quintana-Murci, D.S. Thaler, E. Schurr, L. Abel, and J.L. 
Casanova. 2010. Life-threatening infectious diseases of childhood: sin-
gle-gene inborn errors of immunity? Ann. N. Y. Acad. Sci. 1214:18–33. 
http://dx.doi.org/10.1111/j.1749-6632.2010.05834.x
Andreoni, M., G. El-Sawaf, G. Rezza, B. Ensoli, E. Nicastri, L. Ventura, L. 
Ercoli, L. Sarmati, and G. Rocchi. 1999. High seroprevalence of anti-
bodies to human herpesvirus-8 in Egyptian children: evidence of non-
sexual transmission. J. Natl. Cancer Inst. 91:465–469. http://dx.doi.org/ 
10.1093/jnci/91.5.465
Andreoni, M., L. Sarmati, E. Nicastri, G. El Sawaf, M. El Zalabani, I. Uccella, 
R. Bugarini, S.G. Parisi, and G. Rezza. 2002. Primary human herpesvi-
rus 8 infection in immunocompetent children. JAMA. 287:1295–1300. 
http://dx.doi.org/10.1001/jama.287.10.1295
Avery, D.T., E.K. Deenick, C.S. Ma, S. Suryani, N. Simpson, G.Y. Chew, 
T.D. Chan, U. Palendira, J. Bustamante, S. Boisson-Dupuis, et al. 2010. 
B cell–intrinsic signaling through IL-21 receptor and STAT3 is required 
for establishing long-lived antibody responses in humans. J. Exp. Med. 
207:155–171. http://dx.doi.org/10.1084/jem.20091706
Bisceglia, M., M. Amini, and C. Bosman. 1988. Primary Kaposi’s sarcoma of 
the lymph node in children. Cancer. 61:1715–1718. http://dx.doi.org/ 
10.1002/1097-0142(19880415)61:8<1715::AID-CNCR2820610833> 
3.0.CO;2-P
Boettler, T., F. Moeckel, Y. Cheng, M. Heeg, S. Salek-Ardakani, S. Crotty, 
M. Croft, and M.G. von Herrath. 2012. OX40 facilitates control of 
a persistent virus infection. PLoS Pathog. 8:e1002913. http://dx.doi 
.org/10.1371/journal.ppat.1002913
Boshoff, C., and R.A. Weiss. 2001. Epidemiology and pathogenesis of Kaposi’s 
sarcoma-associated herpesvirus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 
356:517–534. http://dx.doi.org/10.1098/rstb.2000.0778
Bryant, V.L., C.S. Ma, D.T. Avery, Y. Li, K.L. Good, L.M. Corcoran, R. de Waal 
Malefyt, and S.G. Tangye. 2007. Cytokine-mediated regulation of human 
B cell differentiation into Ig-secreting cells: predominant role of IL-21 pro-
duced by CXCR5+ T follicular helper cells. J. Immunol. 179:8180–8190.
Bucheton, B., L. Abel, S. El-Safi, M.M. Kheir, S. Pavek, A. Lemainque, 
and A.J. Dessein. 2003. A major susceptibility locus on chromosome 
22q12 plays a critical role in the control of kala-azar. Am. J. Hum. Genet. 
73:1052–1060. http://dx.doi.org/10.1086/379084
Byun, M., A. Abhyankar, V. Lelarge, S. Plancoulaine, A. Palanduz, L. Telhan, 
B. Boisson, C. Picard, S. Dewell, C. Zhao, et al. 2010. Whole-exome 
sequencing-based discovery of STIM1 deficiency in a child with fatal 
classic Kaposi sarcoma. J. Exp. Med. 207:2307–2312. http://dx.doi 
.org/10.1084/jem.20101597
Cabello, P.H., A.M. Lima, E.S. Azevedo, and H. Krieger. 1995. Familial 
aggregation of Leishmania chagasi infection in northeastern Brazil. Am. J. 
Trop. Med. Hyg. 52:364–365.
Cakir, F.B., E. Cakir, N. Tuzuner, and A. Kut. 2013. Classic Kaposi sarcoma 
with pulmonary involvement mimicking endobronchial tuberculosis 
in a child. Pediatr. Pulmonol. 48:310–312. http://dx.doi.org/10.1002/ppul 
.22635
Camcioglu, Y., C. Picard, V. Lacoste, S. Dupuis, N. Akçakaya, H. Cokura, G. 
Kaner, C. Demirkesen, S. Plancoulaine, J.F. Emile, et al. 2004. HHV-8- 
associated Kaposi sarcoma in a child with IFNgammaR1 deficiency. 
J. Pediatr. 144:519–523. http://dx.doi.org/10.1016/j.jpeds.2003.11.012
Cann, H.M., C. de Toma, L. Cazes, M.F. Legrand, V. Morel, L. Piouffre, J. 
Bodmer, W.F. Bodmer, B. Bonne-Tamir, A. Cambon-Thomsen, et al. 
2002. A human genome diversity cell line panel. Science. 296:261–262. 
http://dx.doi.org/10.1126/science.296.5566.261b
Casanova, J.L., and L. Abel. 2007. Primary immunodeficiencies: a field 
in its infancy. Science. 317:617–619. http://dx.doi.org/10.1126/science 
.1142963
Chang, Y., E. Cesarman, M.S. Pessin, F. Lee, J. Culpepper, D.M. Knowles, and 
P.S. Moore. 1994. Identification of herpesvirus-like DNA sequences 
in AIDS-associated Kaposi’s sarcoma. Science. 266:1865–1869. http://
dx.doi.org/10.1126/science.7997879
Immunohistochemistry. Double immunohistochemical staining of 
OX40L/LANA was accomplished by staining the two antibodies sequen-
tially, using a Bond III Autostainer (Leica). For the first antibody OX40L 
(clone MM0505-8S23, 1:300; Novus Biologicals), after routine preparation 
(air-drying at room temperature for 1 h, then fixing in acetone for 10 min), 
frozen sections were subjected to sequential incubation with the dual endog-
enous enzyme block (Dako) for 5 min, primary antibody at 4°C for 16 h, 
post primary AP for 20 min, polymer AP for 30 min, and mixed red refine 
for 15 min (Bond Polymer Refine Red Detection; Leica). For the second 
antibody LANA (clone LN53, 1:500; Advanced Biotechnologies), OX40L-
stained sections were incubated with the endogenous peroxidase block, pri-
mary antibody, post primary, polymer, diaminobenzidine, and hematoxylin 
for 5, 15, 8, 8, 10, and 5 min, respectively (Bond Polymer Refine Detection; 
Leica). Finally, sections were dehydrated in 100% ethanol and mounted in 
Cytoseal XYL (Thermo Fisher Scientific).
Estimation of the frequency of individuals with biallelic loss-of-
function TNFRSF4 mutations. We assumed that essential splice site muta-
tions, frameshift mutations, stop-gain/loss mutations, and missense mutations 
that are predicted to be damaging by both PolyPhen-2 and SIFT may be 
deleterious (loss of function). Only two OX40 variants reported in the public 
databases (1000 Genomes and Exome Variant Server) fall under these catego-
ries: C31R (minor allele frequency 2.3 × 104) and T62M (minor allele 
frequency 7.7 × 105). Thus, the estimated frequency of individuals hetero-
zygous for one of the possible loss-of-function OX40 alleles would be 6.2 × 
104 (= 2 × [2.3 × 104 + 7.7 × 105] × [1  2.3 × 104  7.7 × 105]), 
and the frequency of biallelic carriers would be 9.5 × 108 (= [2.3 × 104 + 
7.7 × 105]2).
Statistics. Prism software (GraphPad Software) was used to perform unpaired, 
one-tailed Student’s t tests. Values of P < 0.05 were considered significant.
Online supplemental material. Table S1 shows genomic regions with 
positive LOD scores identified by homozygosity mapping of the patient and 
her family members. Table S2 lists variants unique to the patient that are ho-
mozygous and within the intervals identified by linkage analysis. Online sup-
plemental material is available at http://www.jem.org/cgi/content/full/jem 
.20130592/DC1.
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